In our previous instalment, we revealed an international syndicate running online trading ‘scams’ worldwide that had a prominent presence in South Africa. Now we turn to the ‘back office’ running the ...

IDEXX Laboratories' oncology panel and share buybacks boost outlook. Read why IDXX stock is upgraded to buy with growth ...

Explore Eve Holding's Q4 2024 earnings call highlights, featuring eVTOL milestones, $429M liquidity, $14B pre-order backlog, and 2027 certification goals.

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic ...

As the authorities step up enforcement against rodent-related lapses, experts warn that rising urbanisation, climate change ...

AISERA—A leading provider of generative AI solu- tions, Aisera helps enterprises boost revenue, improve user productivity, lower operating expenses, and create magical user experiences ... business ...

A bill that would generate new revenue for the state to address climate change and reduce the risk of future wildfires by ...

Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on ...

Ocugen ( OCGN -3.71%) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...

Conference Call and Webcast Today at 8:30 a.m. ETReached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical ...